Lynn Howie is a hematologist and medical oncologist with extensive clinical practice and regulatory experience. She previously served as a Medical Officer at the FDA where she reviewed and advised Industry and Academia on clinical trial design and regulatory pathways to advance access to novel oncology therapies and devices. Dr. Howie graduated with Honors from the University of North Carolina at Chapel Hill and then earned her medical degree with distinction from the same institution. She completed her internship and residency in Internal Medicine at The Johns Hopkins Hospital. She completed her fellowship training in Hematology and Medical Oncology at Duke University. In addition to her time at the FDA, she has spent time in private practice in western North Carolina.

Dr. Jadvar is a physician-scientist with an academic appointment as tenured Associate Professor of Radiology at the University of Southern California (USC) in Los Angeles. He is also a member of the USC Norris Comprehensive Cancer Center, and Associate Professor of Biomedical Engineering in the USC Viterbi School of Engineering. He received his PhD in bioengineering (1988), from the University of Michigan, Ann Arbor, the MD degree from the University of Chicago Pritzker School of Medicine (1993), Master’s in Public Health (MPH) degree from Harvard University (2005), and the Executive Master’s in Business Administration (MBA) from USC Marshall School of Business (2007). He was an intern in internal medicine at the University of California San Francisco (UCSF) during 1993-94, a diagnostic radiology and nuclear medicine resident at Stanford University, during 1994-98, and a clinical fellow in positron emission tomography (PET) with the Harvard Medical School Joint Program in Nuclear Medicine, during 1998-99. He is past president and fellow of both the American College of Nuclear Medicine (ACNM) and the Society of Nuclear Medicine and Molecular Imaging (SNMMI). He has extensive documented experience in clinical, research, education, administration, radiation safety, outreach, and advocacy for diagnostic and therapeutic nuclear medicine. His research interests include applications of PET in clinical outcome research and in translational molecular imaging research with particular current interest in prostate cancer, theranostics, and targeted radionuclide therapy.